AVROBIO, Inc.

Equities

AVRO

US05455M1009

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 10:38:18 2024-04-25 am EDT			5-day change	1st Jan Change
1.188 ^USD	-0.21%		-4.23%	-12.68%

Mar. 21	North American Morning Briefing : Investors -2-	DJ
Mar. 14	AVROBIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

AVROBIO, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022

November 08, 2022 at 07:15 am EST

AVROBIO, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was USD 22.97 million compared to USD 32.61 million a year ago. Basic loss per share from continuing operations was USD 0.52 compared to USD 0.75 a year ago.
For the nine months, net loss was USD 80.86 million compared to USD 90.9 million a year ago. Basic loss per share from continuing operations was USD 1.85 compared to USD 2.13 a year ago.

Latest news about AVROBIO, Inc.

North American Morning Briefing : Investors -2-	Mar. 21	DJ
AVROBIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Transcript : AVROBIO, Inc., Tectonic Therapeutic, Inc. - M&A Call	Jan. 30
AVROBIO, Inc. entered into an agreement to acquire Tectonic Therapeutic, Inc.	Jan. 29	CI
North American Morning Briefing : S&P 500 Eyes -2-	Dec. 19	DJ
Mizuho Securities Cuts Avrobio Price Target to $2 From $5, Buy Rating Kept	Dec. 18	MT
North American Morning Briefing : Caution Dominates Ahead of CPI Print	Nov. 14	DJ
AVROBIO, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
North American Morning Briefing : China Angst -2-	23-08-15	DJ
AVROBIO, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Wells Fargo Adjusts Price Target on AVROBIO to $2 From $2.50, Maintains Overweight Rating	23-07-13	MT
North American Morning Briefing : Optimism Set to -2-	23-07-13	DJ
Sector Update: Health Care Stocks Slipping Late Wednesday	23-07-12	MT
Sector Update: Health Care Stocks Softer in Afternoon Trading	23-07-12	MT
Wedbush Downgrades AVROBIO to Neutral From Outperform on Halted Development of Gene Therapy Programs, Exploring Alternatives; PT is $2	23-07-12	MT
AVROBIO Says Exploring Strategic Alternatives to Boost Shareholder Value; Shares Jump	23-07-12	MT
Avrobio to Conduct Exploration of Strategic Alternatives	23-07-12	CI
AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell Microcap Index	23-06-23	CI
AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell Microcap Value Index	23-06-23	CI
AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 3000E Index	23-06-23	CI
AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 3000E Value Index	23-06-23	CI
AVROBIO Completes Sale of Gene Therapy Program to Novartis for $87.5 Million	23-06-12	MT
Novartis Pharma AG and Novartis Pharmaceuticals Corporation completed the acquisition of Cystinosis Gene Therapy Program from AVROBIO, Inc..	23-06-08	CI
Sector Update: Health Care Stocks Slightly Higher Late Monday	23-05-22	MT
Sector Update: Health Care Stocks Advancing Monday Afternoon	23-05-22	MT

Chart AVROBIO, Inc.

Duration

Period

More charts

Company Profile

AVROBIO, Inc. is a gene therapy company. The Company is focused on developing potentially curative hematopoietic stem cells (HSC) gene therapies to treat patients with rare diseases following a single dose treatment regimen. The gene therapies that the Company is engaged in developing employ HSCs that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The Company's development focus has been on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies (ERTs). Its pipeline is comprised of three HSC gene therapy programs, which include AVR-RD-02 for the treatment of Gaucher disease type 1 and type 3; AVR-RD-03 for the treatment of Pompe disease, and AVR-RD-01 for the treatment of Fabry disease.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.19 USD

Average target price

2 USD

Spread / Average Target

+68.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AVROBIO, INC.	-12.68%	53.38M
VERTEX PHARMACEUTICALS INCORPORATED	-3.12%	104B
REGENERON PHARMACEUTICALS, INC.	+0.65%	97.42B
ARGENX SE	+1.43%	22.2B
BIONTECH SE	-18.16%	21.23B
GENMAB A/S	-10.90%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-17.30%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+4.56%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.07%	11.66B

Bio Therapeutic Drugs